Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
First Human Subject Enrolled in Lumosa Therapeutics' Phase 1 Trial for LT3001, a New Drug Molecule for Acute Ischemic Stroke 2017-08-01 09:46
1